Filing Overview
Haleon plc filed a Form 6-K covering October 2023. The filing contains a TR-1 notification of a change in major shareholdings by GSK plc and its controlled entities; it does not report quarterly or annual operating results.
Business Context and Reporting Period
The notification concerns Haleon ordinary shares with ISIN GB00BMX86B70. GSK reported that its voting interest crossed a threshold on 6 October 2023 and notified Haleon on 9 October 2023. The Form 6-K is dated 10 October 2023.
Ownership and Key Metrics
| Item | Resulting position | Previous notification |
|---|---|---|
| Voting rights attached to shares | 7.42% | 10.35% |
| Total voting rights held | 685,320,110 | Not clearly provided |
| Voting rights through financial instruments | 0.00% | 0.00% |
The resulting interest consists of 685,320,110 indirect voting rights. Shares are held through Vidacos Nominees Limited under a custody arrangement. The filing states that GSK (No. 1) Scottish Limited Partnership sold part of its interest, while GSK (No. 2) and GSK (No. 3) Scottish Limited Partnerships sold all of their respective interests.
Material Change Versus Prior Notification
- GSK’s disclosed voting interest declined from 10.35% to 7.42%, a reduction of 2.93 percentage points.
- The filing attributes the change to sales by entities indirectly wholly owned by GSK plc.
- The remaining interest is held indirectly through GSK’s controlled undertaking chain and custodian arrangements.
Guidance, Outlook, Risks and Unusual Items
The filing provides no revenue, profit, cash flow, margin, debt, liquidity, guidance or business outlook information. The principal unusual item is the substantial reduction in GSK’s Haleon shareholding. The filing does not state whether GSK intends further sales or describe the effect on Haleon’s operations, governance or market position.
Investor Verification Checklist
- Verify the ownership change against Haleon’s shareholder disclosures and applicable UK major-holdings filings.
- Confirm the number of Haleon shares outstanding used to calculate the 7.42% interest.
- Assess whether GSK’s reduced stake affects future share sales, voting dynamics or strategic relationships.
- Review Haleon’s separate results filings for financial performance, leverage, liquidity and management guidance, none of which are included here.